October brought US approvals involving hepatitis B and rectal-cancer treatment, alongside new oncology data at the major European congress. The ovarian-cancer results included an early-stage investigational programme. These are different stages of clinical and commercial progress: regulatory approval can enable a launch, whereas early …
The half-year release reported revenue growth, improved operating performance and a reaffirmed annual outlook. Productivity and the revised operating model supported the margin narrative, while European demand remained challenging. These developments provide the operating context for the latest small decline rather than evidence of …
• The company’s September 2026 preliminary results reported £1.26 million in revenue for the year ended March 2026, including a record £900,000 of second-half revenue. Investors will be watching whether this momentum continues and whether planned products in China expand sales materially.
• Investors are watching payer coverage, volumes and cash runway; a same-day price catalyst is not independently confirmed.
• Investors are watching regulatory access, recurring demand and margins; a same-day price catalyst is not independently confirmed.
Avacta Group plc has moved into focus after reporting new clinical results for faridoxorubicin, also known as AVA6000, in salivary gland cancers. The company described a near-doubling of progression-free survival and clinically meaningful tumour shrinkage in most patients. The announcement is relevant because oncology …
Bioventix PLC is in focus because the company scheduled publication of its audited full-year accounts for the year ended 30 June 2026. The business occupies a specialist position in diagnostic reagents, developing sheep monoclonal antibodies that are used in clinical diagnostic tests. For investors …
October updates described expanding New Health customer adoption and a rising contribution from repeat business. The enlarged fulfilment line at Sarus Court remained targeted for opening by the end of October. Management also disclosed an indicative working-capital financing proposal, while stressing that no agreement …
Renalytix Plc (LSE:RENX) develops diagnostic tools that help clinicians assess the risk of progressive kidney-function decline. Improving sentiment follows developments in US kidney care policy and plans to expand access to kidneyintelX.dkd. These developments support a cautiously favourable outlook, although commercial delivery remains the …
Oxford Nanopore Technologies Plc (LSE:ONT) is a genomics technology company whose sequencing devices read DNA and RNA by passing molecules through tiny protein pores. The shares moved lower by 2.18% on 23 October 2026 to GBX 206.8, a decline of GBX 4.60. A one-day …